Proteo (PTEO) Stock Price, News & Analysis

Company Overview

Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products. The company focuses on the development of pharmaceuticals based on Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands for use in the treatment of post-surgery damage to tissue; complications resulting from organ transplantation; pulmonary hypertension; and injuries caused by accidents, cardiac infarction, and other diseases. It has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded in 1992 and is based in Irvine, California.

Key Stats

• Today's Range: $0.09 to $0.09
• 50-Day Range: $0.09 to $0.09
• 52-Week Range: $20.00 to $698.00
• Volume: N/A
• Average Volume: 11 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTEO Stock Analysis - Frequently Asked Questions

How have PTEO shares performed this year?

Proteo's stock was trading at $0.0899 at the start of the year. Since then, PTEO stock has increased by 0.0% and is now trading at $0.0899.

How do I buy shares of Proteo?

Shares of PTEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Proteo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteo investors own include ASAP (WTRH), Trigon Metals (TM), SoundThinking (SSTI), PagSeguro Digital (PAGS), Kaya (KAYS) and Energizer (ENR).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PTEO
• CIK: 1063104
• Web: proteo.us
• Phone: +1-949-2534616
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A